Literature DB >> 8402325

Beta 2-microglobulin in postmenopausal osteoporosis.

H Rico1, E Ripoll, M Revilla, P Relea, L F Villa.   

Abstract

The so-called bone-derived growth factor, or beta 2-microglobulin, has a regulatory function in bone metabolism, stimulating osteoclastic activity. Osteoclastic activity is enhanced in postmenopausal osteoporosis, suggesting that beta 2-microglobulin concentration may also be increased in this disease. beta 2-microglobulin concentration was found to be raised (P < 0.001) in 30 women with postmenopausal osteoporosis as compared with 30 normal women of similar age; tartrate-resistant acid phosphatase concentration also was raised (P < 0.001), and total body bone mineral content was decreased (P < 0.001). Linear regression analysis revealed a highly negative correlation result between total body bone mineral content and beta 2-microglobulin (r = 0.577, P < 0.001), and a positive correlation result between beta 2-microglobulin and tartrate-resistant acid phosphatase concentration (r2 = 0.806, P < 0.001). These findings, and the stimulatory effect of beta 2-microglobulin on osteoclastic and osteoblastic activity, suggest that beta 2-microglobulin may play an important role as a local regulatory factor in the pathogenesis of postmenopausal osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402325     DOI: 10.1007/bf01321882

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  21 in total

1.  Immunoreactivity and proliferative actions of beta 2 microglobulin on human bone-derived cells in vitro.

Authors:  D B Evans; M Thavarajah; J A Kanis
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

2.  The association between renal dysfunction and osteopenia in environmental cadmium-exposed subjects.

Authors:  T Kido; K Nogawa; R Honda; I Tsuritani; M Ishizaki; Y Yamada; H Nakagawa
Journal:  Environ Res       Date:  1990-02       Impact factor: 6.498

3.  Serum levels of beta-2-microglobulin--a new marker of activity in Crohn's disease.

Authors:  L Descos; C André; S Beorghia; C Vincent; J P Revillard
Journal:  N Engl J Med       Date:  1979-08-23       Impact factor: 91.245

4.  Tartrate-resistant (band 5) acid phosphatase activity measured by electrophoresis on acrylamide gel.

Authors:  W K Lam; L C Lai; L T Yam
Journal:  Clin Chem       Date:  1978-02       Impact factor: 8.327

5.  Bone remodelling does not decline after menopause in vertebral fracture osteoporosis.

Authors:  J S Wand; J R Green; R Hesp; J N Bradbeer; P N Sambrook; T Smith; L Hampton; J M Zanelli; J Reeve
Journal:  Bone Miner       Date:  1992-06

6.  Bone formation and resorption as the determinants of trabecular bone volume in postmenopausal osteoporosis.

Authors:  B E Nordin; J Aaron; R Speed; R G Crilly
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

7.  Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels.

Authors:  E F Eriksen; S F Hodgson; R Eastell; S L Cedel; W M O'Fallon; B L Riggs
Journal:  J Bone Miner Res       Date:  1990-04       Impact factor: 6.741

8.  Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover.

Authors:  L Scarnecchia; S Minisola; M T Pacitti; V Carnevale; E Romagnoli; R Rosso; G F Mazzuoli
Journal:  Scand J Clin Lab Invest       Date:  1991-10       Impact factor: 1.713

9.  Isolation of growth factors from adult bovine bone.

Authors:  E Canalis; T McCarthy; M Centrella
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

10.  Beta 2-microglobulin induces calcium efflux from cultured neonatal mouse calvariae.

Authors:  S M Moe; S M Sprague
Journal:  Am J Physiol       Date:  1992-09
View more
  3 in total

1.  Beta-2 microglobulins in postmenopausal osteoporosis.

Authors:  Aysen Akinci; Levent Ozçakar
Journal:  Rheumatol Int       Date:  2002-08       Impact factor: 2.631

2.  Beta-2-microglobulin in diseases with high bone remodeling.

Authors:  E Ripoll; I Arribas; P Relea; L Varela; L F Villa; M Revilla; H Rico
Journal:  Calcif Tissue Int       Date:  1995-10       Impact factor: 4.333

3.  The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.

Authors:  Funda Tascioglu; Cengiz Oner; Onur Armagan
Journal:  Rheumatol Int       Date:  2003-03-21       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.